---
document_datetime: 2023-09-21 19:13:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/procomvax-epar-all-authorised-presentations_en.pdf
document_name: procomvax-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.3776526
conversion_datetime: 2025-12-23 21:45:32.571903
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
EU Number

EU/1/99/104/001

Invented name

Procomvax

Strength

1

Pharmaceutical Form

Suspension for injection

Route of Administration

Intramuscular use

<!-- image -->

Medicinal product no longer authorised 1/1 1 Polyribosylribitol phosphate (PRP) from Haemophilus influenzae type b as PRP-OMPC     -7.5 µg Neisseria meningitidis OMPC (outer membrane protein complex of the B11 strain of Neisseria meningitidis subgroup B) Adsorbed hepatitis B surface antigen produced in recombinant yeast cells (Saccharomyces cerevisiae) - 5.0 µg in 0.5 ml.